Tiffany Ahlers: New Senior VP at Mycovia

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

Tiffany Ahlers has been appointed VP at Mycovia Pharmaceuticals. The news was announced today.

In this role, Ms. Ahlers will oversee global commercial operations for the company in addition to supporting business development activities and overall company branding.

“Tiffany’s proven record in leading and managing operations for biopharmaceutical companies will be instrumental as we move toward commercialization of VT-1161 for the treatment of recurrent vulvovaginal candidiasis (RVVC), a disease for which there are no approved treatments in the US,” said Patrick Jordan, Chief Executive Officer of Mycovia. “With Tiffany’s 20 years of cross-functional experience in leading commercial strategy, a global Phase 3 program recruiting ahead of schedule, and an exclusive license agreement with Hengrui Medicine to develop and commercialize VT-1161 in China, Mycovia is building global commercial capabilities in anticipation of launching VT-1161 in 2021. We welcome Tiffany to the team and look forward to working with her as we work to scale our organization into a fully integrated biopharmaceutical company.”

“Joining a company that is paving the path for a potential new treatment paradigm for millions of people living with RVVC and other fungal diseases is a tremendous opportunity,” said Ms. Ahlers. “The Phase 2 data clearly demonstrates VT-1161’s profound efficacy in the treatment of RVVC, and I am thrilled to play a role in translating its clinical potential into commercial reality.”

Ms. Ahlers most recently served as a Senior Vice President at Cello Health Advantage, a boutique market research and consultancy firm, that supports the global pharmaceutical, biotech and health sectors. Previously, she spent almost 10 years at Stallergenes Greer, where she served as Vice President of Marketing and led, developed and managed the daily operations for the US marketing department and the company’s business units. Ms. Ahlers also worked at Cornerstone Therapeutics, which is now Chiesi USA.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.